XML 33 R10.htm IDEA: XBRL DOCUMENT v3.22.4
Certain Balance Sheet Components
 9 Months Ended
Dec. 31, 2022
Other Liabilities Disclosure [Abstract]  
Certain Balance Sheet Components Certain Balance Sheet Components
Cash, Cash Equivalents and Restricted Cash
The following represents a reconciliation of cash and cash equivalents on the unaudited condensed consolidated balance sheets to total cash, cash equivalents and restricted cash in the unaudited condensed consolidated statements of cash flows (in thousands):
December 31,
20222021
Cash and cash equivalents$250,590 $457,742 
Restricted cash (included in other assets)6,168 10,100 
Total cash, cash equivalents and restricted cash$256,758 $467,842 
Cash and cash equivalents include cash deposits in banks and all highly liquid investments that are readily convertible to cash (maturity of three months or less at the time of purchase). Restricted cash consists of funds held or designated to satisfy the requirements of certain agreements that are restricted in their use. As of December 31, 2022 and 2021, restricted cash includes approximately $2.4 million and $7.1 million, respectively, that is held in an escrow fund for use by Sunovion Pharmaceuticals Inc. (“Sunovion”), a subsidiary of Sumitomo Pharma, to manage payments for rebates, chargebacks, and similar fees pursuant to the Market Access Services Agreement (see Note 5(F)).
Inventories
Inventories consisted of the following (in thousands):
December 31, 2022March 31, 2022
Raw materials$15,597 $663 
Work in process6,410 3,737 
Finished goods8,077 3,184 
Total inventories$30,084 $7,584 
Accrued Expenses and Other Current Liabilities
Accrued expenses and other current liabilities consisted of the following (in thousands):
December 31, 2022March 31, 2022
Accrued sales discounts, rebates, and allowances$36,858 $19,390 
Accrued compensation-related expenses23,516 26,389 
Accrued R&D expenses10,244 6,955 
Accrued commercial expenses5,287 7,196 
Accrued royalties payable to Takeda4,400 2,470 
Accrued other expenses3,288 3,309 
Accrued professional fees3,265 1,340 
Accrued income tax payable475 720 
Deferred product revenue— 825 
Total accrued expenses and other current liabilities$87,333 $68,594